Kventiax Prolong

Quetiapine, the active ingredient in Kventiax Prolong, is an atypical antipsychotic presented as an oral tablet for oral use. It is prescribed for the management of schizophrenia, bipolar disorder and as an adjunct in major depressive disorder.

GNH USA supplies Kventiax Prolong as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU quality standards and provides regulatory support for cross‑border procurement, ensuring timely delivery and product integrity across continents.

Quetiapine is used in several psychiatric conditions that involve dysregulation of dopamine and serotonin pathways. - Schizophrenia: reduces psychotic symptoms such as hallucinations, delusions, and thought disorder, improving overall functioning. - Bipolar disorder (manic and depressive episodes): stabilizes mood, decreasing manic elevation and depressive lows, helping maintain emotional balance. - Adjunctive treatment of major depressive disorder: enhances antidepressant response when added to standard therapy, leading to greater symptom remission.

Quetiapine may cause a range of adverse reactions, varying from mild to severe. Common Side Effects: - Drowsiness or sedation - Dry mouth - Constipation - Weight gain Serious or Rare Side Effects: - Extrapyramidal symptoms such as akathisia or tardive dyskinesia - Neuroleptic malignant syndrome, a life‑threatening reaction - Severe orthostatic hypotension or cardiac arrhythmias

When prescribing quetiapine, clinicians should consider several safety precautions. - Assess cardiovascular status: monitor blood pressure and heart rate, especially in patients with pre‑existing hypertension or arrhythmias. - Evaluate metabolic risk: screen for diabetes, lipid abnormalities and weight changes before and during therapy. - Review hepatic and renal function: dose adjustment may be needed in severe impairment. - Caution in elderly patients with dementia: increased risk of mortality and cerebrovascular events. - Avoid abrupt discontinuation: taper gradually to reduce withdrawal or rebound insomnia. - Store at ambient temperature below 25 °C: keep in original container, protect from moisture and light.

Quetiapine interacts with several medicines that can alter its plasma levels or safety profile. Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase quetiapine concentrations, raising risk of toxicity. - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy by lowering drug levels. - CNS depressants (e.g., alcohol, benzodiazepines, opioids): additive sedation and respiratory depression. Moderate Interactions (Monitor Closely): - Antihypertensive agents: enhanced hypotensive effect, monitor blood pressure. - Anticholinergic drugs: may worsen dry mouth and constipation. - QT‑prolonging agents (e.g., certain antiarrhythmics): increase risk of cardiac arrhythmias.